Anocca doses first patient in Sweden with TCR-T therapy
The company treats pancreatic cancer patients using ANOC-001 in the VIDAR-1 trial across four European nations. Early safety signals appear positive.
See the latest news and media coverage for Anocca. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing precision T-cell immunotherapies
anocca.comLast updated
In short: Anocca dosed the first patient in Sweden with its ANOC-001 TCR-T therapy for pancreatic cancer
The company treats pancreatic cancer patients using ANOC-001 in the VIDAR-1 trial across four European nations. Early safety signals appear positive.
The funding will support early-stage clinical trials for its lead programme VIDAR-1, a TCR-T cell therapy.
The funding will support industrial-scale manufacturing and start of clinical trials in 2024
The venture debt will support clinical development of its next-generation T-cell therapies for cancer, targeting a solid tumour indication by 2024.
Anocca has dosed the first patients in its phase 1 VIDAR‑1 clinical programme, marking the initial clinical use of ANOC‑001, a precision TCR‑T cell therapy...
Swedish biotechnology company Anocca has secured approximately Skr440m ($46m) to primarily support...
• First in human-study VIDAR-1 in advanced pancreatic cancer will be conducted at eight leading university hospitals in Sweden, Denmark, Germany and the Netherlands • Anocca is a Swedish...
CTA approval marks Anocca's transition to a clinical-stage company First-in-human VIDAR-1 trial begins with the deployment of ANOC-001 in Advanced Pancreatic Cancer at leading medical...
Track Anocca and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Anocca and other trending companies.